Improving efficiency of initial tests for efficacy in smoking cessation drug discovery

Expert Opinion on Drug Discovery

Volumn 9, Issue 11, 2014, Pages 1259-1264

  Perkins, Kenneth A ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Experimental design; Medication screening; Nicotine dependence; Smoking cessation

Indexed keywords

DRUGS USED IN THE TREATMENT OF ADDICTION;

CLINICAL EFFECTIVENESS; CROSSOVER PROCEDURE; DRUG DEVELOPMENT; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; EVIDENCE BASED PRACTICE; HUMAN; MOTIVATION; OUTCOME ASSESSMENT; PATIENT IDENTIFICATION; PHASE 2 CLINICAL TRIAL; PREDICTIVE VALIDITY; REPRODUCIBILITY; REVIEW; SMOKING CESSATION; STUDY DESIGN; WITHDRAWAL SYNDROME; ANIMAL; DRUG THERAPY; PROCEDURES; SMOKING; TREATMENT OUTCOME;

ANIMALS; DRUG DISCOVERY; HUMANS; SMOKING; SMOKING CESSATION; TREATMENT OUTCOME;

EID: 84911474161     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2014.951632     Document Type: Review

References (27)

1. Ng M, Freeman MK, Fleming TD, et al. Smoking prevalence and cigarette consumption in 187 countries, 1980-2012. JAMA 2014;311(2):183-92
2. Ezzati M, Lopez AD. Estimates of global mortality attributable to smoking in 2000. Lancet 2003;362:847-52
3. Wewers ME, Stillman FA, Harman AM, Shopland DR. Distribution of daily smokers by stage of change: current population survey results. Prev Med 2003;36:710-20
4. Centers for Disease Control and Prevention (CDCP). Quitting smoking among adults-United States, 2001-2010. MMWR Morb Mortal Wkly Rep 2011;60:1513-19
5. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs. sustained-release bupropion and placebo for smoking cessation. JAMA 2006;296:47-55
6. Harmey D, Griffin PR, Kenny PJ. Development of novel pharmacotherapeutics for tobacco dependence: progress and future directions. Nicotine Tob Res 2012;14:1300-18
7. Schnoll RA, Lerman C. Current and emerging pharmacotherapies for treating tobacco dependence. Expert Opin Emerg Drugs 2006;11:429-44
8. US Dept of Health and Human Services (USDHHS). Innovation or stagnation: challenge and opportunity on the critical path to new medical products. (FDA Critical Path Initiative whitepaper). USDHHS; Bethesda MD: 2004
9. Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 2010;9:203-14.
10. Ferry LH, Burchette RJ. Efficacy of bupropion for smoking cessation in non-depressed smokers. J Addict Dis 1994;13:249
11. Lerman C, LeSage MG, Perkins KA, et al. Translational research in medication development for nicotine dependence. Nat Rev Drug Discov 2007;6:746-62.
12. Perkins KA, Stitzer M, Lerman C. Medication screening for smoking cessation: a proposal for new methodologies. Psychopharmacology 2006;184:628-36
13. Perkins KA, Lerman C. An efficient early Phase 2 procedure to screen medications for efficacy in smoking cessation. Psychopharmacology 2014;231:1-11.
14. Baker TB, Piper ME, McCarthy DE, et al. Addiction motivation reformulated: an affective processing model of negative reinforcement. Psychol Rev 2004;111:33-51
15. Tiffany ST, Warthen MW, Goedeker KC. The functional significance of craving in nicotine dependence. In: Bevins RA, Caggiula AR, editors. The motivational impact of nicotine and its. role in tobacco use. Nebraska Symposium on Motivation, Springer Science-Business Media, New York; 2009, 5, 171-97
16. Shiffman S, Johnston JA, Khayrallah M, et al. The effect of bupropion on nicotine craving and withdrawal. Psychopharmacology 2000;148:33-40
17. Perkins KA. Subjective reactivity to smoking cues as a predictor of quitting success. Nicotine Tob Res 2012;14:383-7
18. Herd N, Borland R, Hyland A. Predictors of smoking relapse by duration of abstinence: findings from the International Tobacco Control (ITC) Four Country Survey. Addiction 2009;104:2088-99
19. Fleiss JL. The design and analysis of clinical experiments. Wiley; New York: 1986
20. Ashare R, Wileyto EP, Perkins KA, Schnoll R. The first seven days of a quit attempt predict relapse: validation of a measure for screening medications for nicotine dependence. J Addict Med 2013;7:249-54
21. Ferguson SG, Gitchell JG, Shiffman S, Sembower MA. Prediction of abstinence at 10 weeks based on smoking status at 2 weeks during a quit attempt. Clin Ther 2009;31:1957-65
22. Wileyto EP, Patterson F, Niaura R, et al. Do small lapses predict relapse to smoking behavior under bupropion treatment? Nicotine Tob Res 2004;6:357-67
23. Cleophas TJM. Cross-over studies: a modified analysis with more power. Clin Pharmacol Ther 1993;53:515-20.
24. Glaros AG, Kline RB. Understanding the accuracy of tests with cutting scores: the sensitivity, specificity, and predictive value model. J Clin Psychol 1988;44:1013-23
25. Perrin S. Make mouse studies work. Nature 2014;507:423-5
26. Peck JA, Ranaldi R. Drug abstinence: exploring animal models and behavioral treatment strategies. Psychopharmacology 2014;231:2045-58
27. LeSage MG. Toward a nonhuman model of contingency management: effects of reinforcing abstinence from nicotine self-Administration in rats with an alternative reinforcer. Psychopharmacology 2009;203:13-22